58583-72-5

Usage

Explanation

The compound is composed of 12 carbon atoms, 12 hydrogen atoms, and 3 oxygen atoms.

Explanation

The compound features a carbonyl group (C=O) attached to a benzofuran ring, which is a fused ring system consisting of a benzene ring and a furan ring. Additionally, an ethoxy group (-O-CH2-CH3) is attached to the benzofuran ring.

Explanation

The compound has potential uses in the development of new drugs and materials due to its unique chemical structure and properties.

Explanation

The presence of the benzofuran ring in the compound may contribute to its potential for exhibiting interesting biological activities, which could be useful in the development of new drugs.

Explanation

Further investigation into the compound's potential uses and effects is necessary to fully understand its capabilities and potential applications in the pharmaceutical and materials science fields.

Explanation

The solubility of 1-(7-ethoxy-1-benzofuran-2-yl)ethanone in various solvents is not discussed in the provided material.

Explanation

The stability of the compound under different conditions, such as temperature, pressure, or in the presence of other chemicals, is not discussed in the provided material.

Explanation

The reactivity of 1-(7-ethoxy-1-benzofuran-2-yl)ethanone with other chemicals or under specific conditions is not discussed in the provided material.

Chemical Structure

Ketone with a benzofuran ring and an ethoxy group

Applications

Pharmaceutical and organic synthesis

Biological Activity

Potential for various biological activities

Research Significance

Importance for further research and studies

Solubility

Not mentioned in the material provided

Stability

Not mentioned in the material provided

Reactivity

Not mentioned in the material provided

InChI:InChI=1/C12H12O3/c1-3-14-10-6-4-5-9-7-11(8(2)13)15-12(9)10/h4-7H,3H2,1-2H3

Upstream product

• 40020-87-9 2-acetyl-7-hydroxybenzofuran 
• 75-03-6 ethyl iodide 
• 492-88-6 3-ethoxysalicylaldehyde 
• 78-95-5 chloroacetone 

Relevant academic research and scientific papers

Novel 1-(7-ethoxy-1-benzofuran-2-yl) substituted chalcone derivatives: Synthesis, characterization and anticancer activity

Cancer treatment still requires new compounds to be discovered. Chalcone and its derivatives exhibit anticancer potential in different cancer cells. A new series of benzofuran substituted chalcone derivatives was synthesized by the base-catalyzed Claisen-

Synthesis and Anti-Cholinesterase Activity of Novel Glycosyl Benzofuranylthiazole Derivatives

Abstract: A new series of glycosyl benzofuranylthiazole derivatives were designed, synthesized, characterized, and evaluated as potential candidates to treat Alzheimer’s disease. The compounds have been synthesized by the cyclocondensation of glycosyl thiourea with a variety of 2-(bromoacetyl)benzofurans. The reaction conditions have been optimized, and good yields (79–95%) have been obtained. The synthesized compounds showed different degrees of cholinesterase inhibitory activity.

Selective agonist of dopamine D2 receptor (DRD2) and application thereof in treatment of diseases

The invention relates to a selective agonist of DRD2 and application thereof in treatment of diseases. Specifically, the invention discloses an agonist with high selectivity to DRD2 for the first time. The structure of the agonist is shown as a formula I.

Synthesis and bioactivity of novel C2-glycosyl benzofuranylthiazoles derivatives as acetylcholinesterase inhibitors

A new series of C2-glycosyl benzofuranylthiazole derivatives was synthesised by the further cyclization of glycosyl thiourea and 2-(bromoacetyl)-benzofuran via Hantzsch’s method. The corresponding 2-(bromoacetyl)-benzofuran derivatives were obtained by the reaction from various salicylaldehydes, and the glycosyl thiourea was prepared through a series of steps from D-Glucosamine. The acetylcholinesterase-inhibitory activities of the products were tested by Ellman’s method. The most active compounds were subsequently evaluated for the 50% inhibitory concentration values. N-(1,3,4,6-tetra-O-benzyl-2-deoxy-β-D-glucopyranosyl)-4-(5-methoxy-benzofuran-2-yl)-1,3-thiazole-2-amine possessed the best acetylcholinesterase-inhibition activity with a 50% inhibitory concentration of 2.03 ± 0.26 μM.

NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.

Benzofuran derivatives useful in treating diabetic complications

A benzofuran derivative having the general formula (I): STR1 wherein R1 is hydrogen atom, a benzyl group, unsubstituted or substituted with a halogen atom or an alkyloxy group, or an alkyl group having 1 to 3 carbon atoms, R2 is hydrogen atom or an alkyl group having 1 to 3 carbon atoms, R3 is acetyl group, ethyl group, carboxyl group or 4-methyl-2,5-dioxoimidazolidine-4-yl group, R4 is hydrogen atom, hydroxyl group, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 9 carbon atoms, carboxymethoxy group, nitro group, acetoamino group, a benzylozy group unsubstituted or substituted with a halogen atom, nitro group or an alkyloxy group or a group having the formula: --OR6, wherein R6 is an alkenyl group having 2 to 4 carbon atoms or an alkyl group having 2 to 3 carbon atoms having a halogen atom, cyano group or oxo group, R5 is hydrogen atom or methylenedioxy group together with R4 group, n is 1 or 2, and the unsubstituted or substituted N-carboxymethylsulfamoyl group, R4 and R5 are attached at 3-position, 4-position, 5-position, 6-position or 7-position of the benzofuran ring, or a nontoxic salt thereof, process for preparing the same and a pharmaceutical composition containing the same. The compounds of the present invention have powerful aldose reductase inhibiting activity, platelet aggregation inhibiting activity and arachidonic acid metabolism inhibiting activity and are useful for a remedy for treatment of diabetic complications.